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1. SUMMARY 
 
Metabolic syndrome (MetS) is associated with clustering of cardiovascular risk factors 
in individuals that may greatly increase their risk of developing coronary artery disease. 
Obesity and related metabolic dysfunction are the driving force in the prevalence of MetS. It 
is believed that obesity has detrimental effects on cardiovascular function, but its overall 
impact on the vasomotor regulation of small coronary arteries is still debated. We aimed to 
examine the impact of obesity on the vasomotor function of large conduit vessels and small 
coronary arterioles. We have found that in the brachial artery there was a positive correlation 
between flow-mediated (FMD)- and nitroglycerin (NTG)-induced dilations and body mass 
index (BMI) in obese patients.  
In animal model of diet-induced obesity, we demonstrated that due to the activation of 
soluble guanylate cyclase the sensitivity of vascular smooth muscle cells to nitric oxide is 
enhanced, which contributes to the enhanced coronary arteriolar dilations to nitric oxide 
donors.  
Our data indicate that in obesity arteries adapt to hemodynamic changes via up-
regulating cellular mechanism(s) intrinsic to the vascular wall. A better understanding of 
mechanisms that may contribute vascular adaptation may provide insight into the sequence of 
pathological events in obesity and may allow the harnessing of these effects for therapeutic 
purposes. 
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2. BACKGROUND 
 
Metabolic syndrome (MetS) is associated with a clustering of cardiovascular risk 
factors in individuals that may greatly increase their risk of developing ischemic heart disease 
and heart failure. Abnormalities in the vasomotor function of the coronary microvessels 
occurs in MetS; and in some instances these abnormalities represent important markers of risk 
or may even contribute to the pathogenesis of myocardial dysfunction. Obesity and its related 
metabolic dysfunction are the driving force in the prevalence of MetS and the development of 
type 2 diabetes. The coronary microcirculation is currently being therapeutically targeted 
aiming to prevent or delay the development of cardiac contractile dysfunction, heart failure 
and ischemic heart disease, which remains the major challenge in reducing morbidity and 
mortality in patients with MetS. 
 
2.a. Progression of coronary vasomotor dysfunction in MetS 
 
Although acute and chronic ischemic syndromes are commonly due to coronary flow-
limiting atherosclerotic plaques in epicardial coronary arteries, about 10 to 20% of patients 
with cardiac symptoms undergoing cardiac catheterization are found to have normal coronary 
angiograms (11). It has been demonstrated that despite the presence of angiographically 
normal coronary arteries coronary flow reserve is reduced in diabetic patients (57). Thus, it 
has been suggested that epicardial atherosclerosis may not be the only underlying pathology 
resulting in abnormal coronary flow reserve in diabetic patients (55, 57). In type 2 diabetic 
patients impaired acetylcholine (ACh)-induced, endothelium-dependent relaxation of brachial 
artery (18) and forearm resistance vessels has been reported earlier (26, 49, 70). Performing 
quantitative angiography, Nitenberg at al has demonstrated impaired coronary dilation using 
the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries 
(56). Using similar methodology, Kaneda et al have performed a study, in which 165 patients 
underwent intracoronary injection of ACh and found that diabetes was the strongest predictor 
for ACh-induced vasospasm, as an indicator of endothelial dysfunction (37). Moreover, in 
coronary arterioles isolated from the heart of diabetic patients, Miura et al demonstrated an 
impaired hypoxia and ATP-dependent, potassium channel-mediated vasodilation (50). Thus, 
strong evidence indicates that in MetS development of diabetes mellitus is associated with 
impaired vasodilator responses of both peripheral and coronary microvessels. 
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Data obtained in animal models of MetS also indicate that presence of fasting 
hyperglycemia, hence presence of manifest diabetes, impairs coronary vasodilation to 
agonists and to increases in intraluminal flow (10, 13, 15, 47, 65). Oltman et al have 
demonstrated that in Zucker diabetic fatty (ZDF) rats coronary arteriolar dilation to ACh is 
diminished, whereas dilation in prediabetic, younger (8-12 weeks old) animals are preserved 
(59). Of note, in pre-diabetic obese Zucker rats or in animals fed a high fat diet, with mild 
elevation of fasting glucose levels, impaired vasodilator function has been reported in vessels 
from the mesentery (59), cerebral (21, 22) and skeletal muscle vascular beds (19, 24). In 
contrast, in the obese Zucker rats and also in animals fed a high fat diet, recent studies found 
preserved (31, 34, 41) or even augmented coronary dilations (60). Thus, it seems that during 
the progression of MetS while coronary vasomotor function is protected before the 
development of type 2 diabetes, peripheral microvessels exhibit impaired vasomotor 
regulation. 
To address this discrepancy it has been posited that, as compared to the vascular beds 
of the periphery, coronary microvessels are more “resistant” to development of vasomotor 
dysfunction (40). This implies, that coronary vessels either have efficient mechanisms, which 
protect their vasomotor function, or that coronary vessels have mechanisms that can actively 
compensate for the loss of vasomotor pathways, as metabolic disease progresses (25, 68). 
Since in the coronary circulation oxygen extraction is near maximal (71), any impairment in 
arteriolar dilator function could have significant consequences on myocardial perfusion. As 
described by Chilian, the coronary circulation matches blood flow with oxygen requirements 
by coordinating the resistances within different-sized vascular beds, each governed by distinct 
regulatory mechanisms (14, 36). Such integration in the coronary circulation is believed to be 
advantageous because the system does not rely on a single mechanism of control, i.e. 
myogenic, flow or metabolic regulation of vascular resistance (51). An integration of 
vasomotor regulatory systems in the coronary circulation seems especially important in 
obesity and MetS, conditions in which metabolic and hemodynamic changes require 
adaptation of coronary vasomotor regulation. 
In MetS there could be several factors that can be implicated necessitating adaptation 
of coronary vessels. In MetS, the impact of these pathological factors is difficult to discern 
owing to the close interrelationships between obesity, insulin resistance, type 2 diabetes, 
hypertension and other known and as yet unidentified pathological factors (16, 17). Yet, 
several previous and recent studies raised the possibility that the early adaptation of the 
coronary circulation can be attributed specifically to obesity and/or obesity-related changes in 
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metabolic and hemodynamic regulation. On the other hand, adaptive vasomotor responses in 
the coronary circulation may decline as MetS progresses and other co-morbid diseases 
develop, such as, severe insulin resistance, hypertension and fasting hyperglycemia (diabetes). 
This may lead to limited vasomotor function (both dilator and constrictor functions can be 
diminished at advanced state of a disease) of coronary microvessels that are primarily 
responsible for adjusting cardiac perfusion to actual metabolic demand. 
 
2.b. Obesity and cardiovascular regulation 
 
We make no attempt to provide a detailed description of the impact of obesity on 
complex hemodynamic regulation or the functional and structural changes of the heart but 
refer to a comprehensive recent review (1). Of particular importance, is the widely accepted 
view that obesity is independently associated with left ventricular hypertrophy. A large body 
of evidence indicates that an increase of left ventricular mass, in the long term, leads to 
diastolic and systolic cardiac contractile dysfunction in obese patients (1). It has been also 
posited that in “uncomplicated” (lack of co-morbid conditions such as hypertension, diabetes 
etc.) obesity associated increases in left ventricular mass can be appropriate for body size 
(33). Thus, early “physiological” adaptation of cardiac function can be envisioned, which will 
accommodate for the higher hemodynamic and metabolic demand in obesity. It is known that 
any increase in body mass (muscular or adipose tissue) requires a higher cardiac output and 
expanded intravascular volume to meet the elevated metabolic requirements (43). It is also 
believed that obesity is associated with a hyperdynamic circulation and increased cardiac 
output (43). Correspondingly, a study by Jern et al (35) has demonstrated that cardiac output 
and stroke volume were positively related to body mass index (BMI), but inversely to 
waist/hip ratio. They also found that total peripheral resistance was inversely correlated to 
BMI, whereas high waist/hip ratio was associated with higher systemic vascular resistance 
(35). This implies that increased BMI can be associated with increased cardiac output and 
lower peripheral vascular resistance, but visceral obesity, which is the case in many obese 
patients, is associated with lower cardiac output and higher total peripheral resistance. 
Whether these changes can be attributed to an altered cardiac structure or contractile 
dysfunction or whether they can be related to alterations in the function of coronary and 
peripheral resistance vessels is not known. The impact of obesity on complex cardiovascular 
regulation over the course of progression of MetS clearly requires further mechanistic 
investigations. 
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2.c. Impact of obesity on vasodilator function 
 
Morphological changes in microvessels are quite rare in obesity prior to the 
development of hyperglycemia. Obesity-related pathological alterations, including 
atherogenic dyslipidemia, insulin resistance and hyperinsulinemia are believed to impair the 
vasomotor function of small arteries. However, blood flow to the various organs systems is 
rarely impaired in obesity, unless atherosclerosis of the arteries develops. Throughout life, 
organs receive normal or even greater than normal blood flow in obese subjects (29). Yet, 
convincing evidence of the impact of obesity on vasomotor regulation of coronary 
microvessels is lacking at present. Such demonstration is hampered by issues regarding direct 
investigation of coronary microcirculation both in humans and animal models (14, 61); and 
also by the impact of several, combined risk factors present in obesity. 
 
Studies on obese patients 
Central obesity was found to be associated with reduced bradykinin- or hyperemia-
induced forearm blood flow (30, 73). It has been shown that obese children already exhibit 
impaired brachial artery relaxation to hyperemic flow (38). Forearm resistance vessels also 
exhibited reduced acetylcholine (ACh) and NO-donor (sodium nitroprusside)-induced 
dilations in obese humans (64). Interestingly, it has been posited that body fat distribution, 
rather than body weight increase is responsible for the impaired brachial artery dilation (30) 
and elevation of peripheral vascular resistance in obesity (35), an idea, which is further 
supported by a theoretical analysis using physiological measurements obtained in obese 
patients (23). 
Only a limited number of studies are available that investigated alterations in 
vasomotor responses of coronary microvessels in obese patients. Because other studies (2, 69) 
have demonstrated a close association between coronary vasomotor function and relaxation of 
brachial artery it was speculated that obesity may also adversely affect coronary dilations. 
Indeed, myocardial blood flow, as measured by positron emission tomography, was found to 
be significantly reduced in postmenopausal women with obesity, which was negatively 
correlated with waist/hip ratio (48). These observations indicated that obesity, especially in 
the presence of co-morbidities, such as hypertension and diabetes, is not necessarily 
associated with impaired vasodilator function of coronary microvessels. On the contrary, it is 
possible that the presence of obesity has potentially a key role in maintaining and augmenting 
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vasodilator capacity of coronary microvessels. Interestingly, clinical studies on obese patients 
with coronary heart disease have found an unexpectedly favorable prognosis on acute 
cardiovascular outcome, with the worst prognosis associated with either underweight or 
morbidly obese patients (27, 28, 32). 
Although obesity is widely accepted as a risk factor for coronary heart disease and 
heart failure, emerging evidence supports a protective role of obesity once patients have 
developed cardiovascular disease (28, 32). 
 
Studies in animal models of obesity 
Disturbed regulation of microvascular vasomotor function in animal models of obesity 
is similar in characteristics that seen in humans. This similarity also applies to the discrepant 
findings obtained in various vascular beds, in different models of obesity. In the obese, 
JCR:LA-corpulent rats an impaired endothelium-dependent relaxation of aorta (8) and 
reduced dilations of mesenteric arteries to ACh (58) have been reported. Reduced mesenteric 
(53) and skeletal muscle (19) arteriolar dilation to ACh was also found in rats fed a high fat 
diet. In obese Zucker rats it has been reported that in mesenteric arterioles endothelium-
dependent relaxation to ACh was preserved at 20-week old, but was reduced in 32-week old 
animals (67). In a similar experimental design, Oltman et al have investigated the progression 
of coronary and mesenteric arterial dysfunction in the Zucker obese rat. They found that 
coronary arteriolar dilation to ACh was preserved in 16-24 week old animals, but dilations 
became diminished in 28-36 week old rats, when compared to lean controls (59). Mesenteric 
arterioles of Zucker rats exhibited relatively maintained dilations to ACh at both ages (59). 
Katakam et al reported that in 12-week old obese Zucker rats ACh-induced dilations of small 
coronary arteries was preserved, although they found a reduced vasodilation to insulin (39). 
These studies concluded that arteriolar dilations in obese animals can be preserved at younger 
age (i.e. at the early state of disease), but vascular dysfunction progresses and this progression 
can be at a different rate in different vascular beds, such as in coronary and mesenteric 
vessels. 
 More importantly, the early study by Subramanian et al found that relaxation of aorta 
to ACh is enhanced at ages of both 20 and 32-week old obese Zucker rats animals (67), 
results similar to those observed earlier by Auguet et al (3). In mice fed a high fat diet, an 
enhanced endothelium-dependent, hydroxyl radical-induced relaxation in the femoral artery 
has been also reported (6). Coronary arterioles from female pigs fed a high fat diet exhibited 
only modest impairment of dilation to bradykinin (31), whereas coronary dilations to ACh 
 12 
were preserved in the obese Zucker rats (39) and in rats fed a high fat diet (34). More 
intriguing, Prakash et al have reported that ACh-induced dilations of coronary arterioles from 
obese Zucker rats were markedly enhanced (more than 25% increase in diameter, when 
compared to lean animals) (60). These latter observations imply that although coronary 
dysfunction progresses with obesity, coronary vasodilator function can be preserved or even 
augmented at early phases of the disease. 
Collectively, on the basis of these aforementioned human and animal studies we have 
raised the hypothesis that vessels (both coronary and peripheral) adapt to obesity by 
maintaining or enhancing their dilator function to increase blood flow to higher metabolic 
demand. Emerging evidence indicate that hemodynamic adaptation is not a passive 
phenomenon, but requires active participation of various cellular pathways at vascular level. 
The nature of these cellular pathways that are responsible for vascular adaptation to obesity is 
incompletely understood. Elucidating these cellular mechanisms seems important, not only 
because they provide insight into the sequence of pathological events in obesity, but also 
because they could be harnessed for therapeutic purposes. 
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3. AIMS 
 
These aforementioned findings led us to the hypothesis that obesity activates, as yet unknown 
adaptive mechanisms intrinsic to the vascular wall, aiming to maintain adequate tissue 
perfusion. 
 
Thus, the aims were: 
 
1) To investigate the impact of obesity on the endothelium-dependent and –independent 
dilations of the human brachial artery; and 
 
2) To investigate the impact of obesity in animal model (Wistar rat) on coronary arteriolar 
vasomotor function, to examine the vascular adaptation and the possible cellular 
mechanisms involved. 
 
Since nitric oxide (NO) plays an important role in regulating both brachial artery and 
coronary arteriolar dilations we have focused our investigation on the possible alterations in 
NO-mediated vasomotor function. 
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4. METHODS 
 
4.a. Assessment of brachial artery relaxation 
 
All protocols were approved by the Ethical Committee at the University of Debrecen, 
Medical and Health Science Center. All patients were given written information about 
experimental interventions. Assessment of brachial artery relaxation was performed in 
patients (N=55), who were recruited locally. 
Ultrasound measurements of the brachial artery were performed according to the 
method described by Celermajer et al (12), using high-resolution ultrasounds with a 7.5-MHz 
linear array transducer. Diameter measurements of the right brachial artery were taken at rest 
after supine rest for at least 10 minutes, after cuff deflation completing suprasystolic 
compression (at least 50 mmHg above systolic pressure) of the right upper arm for 4.5 
minutes, and after sublingual application of 0.4 mg of nitroglycerin. Scans were taken of the 
brachial artery proximal to the bifurcation of the radial and the ulnar artery by the same 
ultrasound operator. Lumen diameters were measured from one media-adventitia interface to 
the other at least 3 times at baseline, every 20 seconds after reactive hyperemia, and 
subsequent to the administration of nitroglycerin. The maximum relaxation to hyperemic flow 
(flow mediated dilation, FMD) and to nitroglycerin (NTG) were taken as the average of the 3 
consecutive maximum diameter measurements. Vasodilation was then calculated as the 
percent change in diameter over the baseline value. 
 
4.b. Animal model of obesity 
 
Male Wistar rats (N=50) were purchased from Charles River Laboratories. Rats were 
maintained in the animal care facility with a 12-hour light/dark cycle and were given free 
access to food and water. Rats were maintained on standard rat chow (N=25) or on high-fat 
diet (N=25), (European Union-modified rodent diet with 60% fat, 58Y1, TestDiet, PMI 
Nutrition International) for 10 weeks (10). All protocols were approved by the Institutional 
Animal Care and Use Committee. 
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4.c. Isolation of rat coronary arterioles. 
 
With the use of microsurgical instruments and an operating microscope, the second 
branch of septal artery (~1.5 mm in length) running intramuscularly was isolated and 
cannulated. The cannulated arteriole was connected with silicone tubing to a pressure servo 
control system (Living Systems Instrumentation, VT, USA) to set the intraluminal pressure to 
80 mmHg. Changes in arteriolar diameter were continuously recorded with a digital camera 
(CFW1310, Scion Corp, USA), connected to a microscope (Nikon, Eclipse 80i) (2). 
 
4.d. Assessment coronary arteriolar responses 
 
During an incubation period of 1 hour, a spontaneous myogenic tone developed in the 
isolated coronary arterioles in response to the intraluminal pressure of 80 mmHg. Cumulative 
concentrations of the endothelium-dependent vasodilator, acetylcholine (ACh, 1 nmol/L – 1 
μmol/L) were administered to the coronary arterioles from lean and obese rats in the presence 
and absence of N
ω
-nitro-L-arginine-methyl-ester (L-NAME; 200 μmol/L, for 30 min), an 
inhibitor of the NO synthase, and changes in diameter were measured. Then, arterioles were 
incubated with soluble guanylate cyclase (sGC) inhibitor, oxadiazolo-quinoxaline (ODQ, 10 
μmol/L, for 30 min) and arteriolar responses to ACh were obtained again in the 2 groups. In 
the separate set of experiments, dilations to cumulative concentrations of NO donor, sodium 
nitroprusside (SNP, 1 nmol/L – 10 μmol/L) was investigated in isolated coronary arterioles of 
lean and obese rats. Then, arterioles were incubated with ODQ (10 μmol/L, for 30 min) and 
arteriolar responses to NO donor were reassessed. In another series of experiments increasing 
concentrations of 8-bromo-cGMP, a cell permeable cGMP analog (1 nmol/L – 10 μmol/L) 
was administered and changes in diameter were measured. In isolated vessels agonist-induced 
arteriolar responses were expressed as changes in arteriolar diameter as a percentage of the 
maximal dilation defined as the passive diameter of the vessel at 80-mmHg intraluminal 
pressure in a Ca
2+
-free medium. 
 
4.e. cGMP immunocytochemistry 
 
The sGC activity was detected in coronary arterioles through the identification of basal 
and NO donor-stimulated increases in cGMP immunoreactivity, by using antibody against 
cGMP, similarly as it was described previously (12). Briefly, the left ventricle including the 
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coronary arteriole was embedded and frozen in optimal cutting temperature compound (Tissue 
Tek, Electron Microscopy Sciences). Unfixed consecutive sections (10-μm thick) were 
transferred to a solution containing 1 μM SNP in physiological salt solution (PBS) and 
incubated for 15 min at 37 ºC. Other sections remained in PBS solution during the 15-min 
incubation period and served as unstimulated controls. Sections were than fixed with acetone 
and immunolabeled with a monoclonal anti-cGMP primary antibody (dilution 1:2000, Sigma 
Inc). Immunostainings were visualized by using avidin-biotin horseradish peroxidase 
visualization system (Vectastain kit, Vector Laboratories), stained with diaminobenzidine 
(DAB). For nonspecific binding, the primary antibody was omitted. Images of the sections 
were collected with a digital camera (CFW 1310C, Scion Corp) connected to a Nikon Eclipse 
80 microscope. For semi quantitative analysis of the cGMP immunoreactivity, in defined 
areas of the arteriolar wall (6 separate regions in each arteriole with diameter of ~100-150 
μm) the amount of the brown product (DAB) was estimated by measuring optical density 
using the NIH Image software. Background (absence of the first antibody) subtracted, 
averaged optical density was then calculated and compared in coronary arterioles of lean and 
obese rats. 
 
4.f. cGMP ELISA 
 
The sGC activity was detected in the carotid artery through the identification of basal 
and NO donor, SNP-stimulated increases in cGMP levels, which was measured with 
commercially available ELISA kit (Assay Design Inc, Ann Arbor, USA) following the 
instructions by the manufacturer. 
 
4.g. Immunoblots 
 
Single coronary arteries (one vessel from each animal) were dissected from the hearts 
of lean and obese rats, cleared of connective tissue and briefly rinsed in ice-cold PBS. After 
the addition of 20 μl of Laemmli sample buffer (from Sigma Inc.) tissues were homogenized. 
Immunoblot analysis was carried out as described before (3). The antibodies used for 
detection of protein expression (anti-eNOS IgG and anti-sGC ß1 subunit IgG) were obtained 
from Sigma Inc. Anti-ß-actin IgG obtained from Abcam Inc was used as loading control. 
Signals were revealed with chemiluminescence and visualized autoradiographically. Optical 
density of bands was quantified and normalized for ß-actin by using NIH Image software. 
 17 
 
4.h. Statistical analysis 
 
Data were stored and analyzed with the NCSS statistical software (Kaysville, Utah, 
USA). Test selection was based after evaluating the variables for normal distribution, 
employing the Kolmogorov-Smirnov test. In the human studies, testing differences of 
different variables between groups was accomplished by two-way analysis of variance 
(ANOVA) followed by Tukey-Kramer multiple comparison test. One-way ANOVA followed 
by Tukey posthoc test was performed to compare differences in brachial artery responses, 
which was investigated only in hypertensive patients. Since all the obtained data in this study 
met the normality criteria accomplished by Kolmogorov-Smirnov test, associations between 
continuous variables were analyzed by the Pearson correlation test. To examine categorical 
variables two-way ANOVA was performed. Those associations, which were significant on 
univariate analysis, were entered into a multiple regression model, adjusted for the significant 
covariates. In a linear regression analysis the slopes of regression lines were calculated. In the 
animal studies Statistical analyses were performed using GraphPad Prism Software (San 
Diego California USA) by two-way repeated-measures ANOVA followed by Tukey's posthoc 
test or Student's t-test as appropriate. Data are expressed as means±S.E.M. P<0.05 was 
considered statistically significant. 
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5. RESULTS 
 
5.a. Brachial artery relaxation to hyperemic flow and nitroglycerin in patients with 
hypertension 
 
In order to reveal the impact of obesity on vasomotor function brachial artery dilations 
were assessed by high resolution ultrasound.  
Patient demographics are summarized in Table 1. 
 
Table 1. Demography of Patients Underwent Brachial Artery Ultrasound Investigation 
 
Characteristics N=55 
Sex, male (%)     34 (61.8) 
Age (years)      59±11 
Systolic Blood Pressure (mmHg)   153±15 
Diastolic Blood Pressure (mmHg)   93±10 
Body mass index (BMI)    29±4 
 
Underlying disease N, (%) 
Diabetes Mellitus     20 (36.4) 
Hypercholesterolemia    41 (77.4) 
Coronary artery disease    9 (16.3) 
Previous myocardial infarction   5 (9.4) 
 
Medications N, (%) 
ß-blockers      26 (47.3) 
ACE inhibitor     40 (72.7) 
Diuretics      15 (27.3) 
Nitrates      1 (1.8) 
Lipid lowering     23 (41.8) 
 
Data are mean±SD. N indicates the number of patients studied. 
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In the study population the mean value of FMD was 5.0±0.4%, whereas the mean 
value of NTG-induced dilation was 16.1±0.6%. Interestingly, when patients were divided to 
lean (BMI<25), overweight (BMI between 25 and 30) and obese subgroups (BMI>30), FMD 
(Figure 1a) and NTG-induced dilations of brachial artery (Figure 2a) were significantly 
enhanced between the lean and obese subjects (FMD, lean vs. obese: P=0.026, overweight vs. 
obese: P=0.011 and NTG, lean vs. obese: P=0.023). 
 
Figure 1, Panel a: Summary data of flow-mediated dilation (FMD) of the brachial artery in 
lean (N=11), overweight (N=21) and obese (N=23) patients with hypertension. Data are 
mean±SEM. *,P<0.05, Panel b: Pearson correlation between FMD and BMI in hypertensive 
individuals (N=55, regression line is included in the Figure). 
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Correspondingly, Pearson correlation revealed a significant, positive correlation 
between BMI and FMD (Figure 1b) and also between BMI and NTG-induced (Figure 2b) 
brachial artery dilations. 
 
Figure 2, Panel a: Summary data of nitroglycerin (NTG)-induced brachial artery dilations in 
lean (N=11), overweight (N=21) and obese (N=23) patients with hypertension. Data are 
mean±SEM. *, P<0.05, Panel b: Pearson correlation between NTG-induced dilations and 
BMI in hypertensive individuals (N=55, regression line is included in the Figure). 
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Vessel size and hyperemia were similar in lean, overweight and obese patients, thus, it 
can be assumed that the stimulus for FMD was similar in the groups studied. Also, images 
taken in lean and obese subjects were comparable in quality and resolution making feasible 
for the comparison of patients according to their body weight (Figure 3). 
 
 
Figure 3, Representative images obtained from lean (Panels a and b) and obese patients 
(Panels c and d) at baseline (Panels a and c) and after nitroglycerin (NTG) administrations 
(Panels b and d), showing a comparable quality and resolution of the images in lean and 
obese subjects making feasible for the comparison of patients according to their body weight.  
 
 
In addition to a significant, positive correlation between BMI and brachial artery 
dilations, a significant, negative correlation was found between FMD and age (r= -0.32, 
P=0.021), but not between NTG-induced dilations and age (r= -0.15, P=0.285). Thus, this 
 22 
variable was then used in the multiple regression analysis, as a covariate. Correlations 
between BMI and FMD and also BMI and NTG-induced dilations, however, remained 
significant after adjusting for age (FMD vs. BMI: P=0.047 and NTG vs. BMI: P=0.007). No 
significant correlations were found in any other variables investigated on FMD (gender/male: 
P=0.196, diabetes mellitus: P=0.200, coronary artery disease: P=0.499, high cholesterol 
levels: P=0.611, β-blockers: P=0.428, ACE-inhibitors: P=0.317, Diuretics: P=0.230, Lipid 
lowering drugs: P=0.922) and also on NTG-induced brachial artery dilations (gender/male: 
P=0.245, diabetes mellitus: P=0.415, coronary artery disease: P=0.108, high cholesterol 
levels: P=0.541, β-blockers: P=0.619, ACE-inhibitors: P=0.980, Diuretics: P=0.566, Lipid 
lowering drugs: p=0.570). 
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5.b. Results in animal model of obesity 
 
After commencing of high fat diet for 10 weeks the body weight, serum insulin, 
glucose, and total cholesterol levels of rats became significantly greater, when compared to 
those of rats fed the standard diet (Table 2). Also, we have found that the C-reactive protein 
levels were similar in the two groups of animals (Table 2). It should be noted that we have 
found a significant elevation in fasting glucose levels in this model of diet-induced obesity. 
However, the glucose levels were only slightly elevated in obese rats (Table 2), as compared 
to other animal models of type 2 diabetes, such as the db/db mice (2) or the diabetic Zucker 
rats (13), in which animals have about 4-times higher fasting glucose levels. 
 
Table 2: Characteristic of rats after 10 weeks of normal diet (lean) and  
high fat diet (obese) 
 Lean (n=20) Obese (n=20) 
 
body weight (g) 376±16 569±17 * 
 
serum glucose (mmol/L) 6.5±0.3 9.6±0.7* 
 
serum insulin (pmol/L) 91±11 221±19* 
 
serum total cholesterol (mmol/L) 1.20±0.08 1.62±0.07* 
 
C-reactive protein (mg/L) 0.12±0.01 0.14±0.01 
 
 
Data are mean±SEM. * indicate significant difference, p<0.05  
 
Coronary arteriolar responses to ACh.  
In coronary arterioles isolated from lean and obese rats there were no significant 
differences between the spontaneously developed arteriolar tone (86±6 μm and 97±6 μm, 
respectively) and in the passive arteriolar diameters (in Ca
2+
-free medium, 153±9 μm and 
149±7 μm, at 80 mmHg intraluminal pressure, respectively). We have found that 
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endothelium-dependent dilations to ACh were not significantly different between coronary 
arterioles of lean and obese rats (Figure 4a). Inhibition of NO synthesis with L-NAME 
decreased ACh-induced dilation in coronary arterioles isolated from lean animals (Figure 4b), 
whereas it had not significant effect on ACh-induced responses in arterioles of obese rats 
(Figure 4c). Administration of ODQ, an inhibitor of soluble guanylate cyclase elicited similar 
reduction in ACh-induced dilations in coronary arterioles of the two groups of animals 
(Figure 4d). 
 
Figure 4, Changes in diameter of coronary arterioles isolated from lean (n=18) and high fat 
diet-induced obese rats (n=19) in response to cumulative concentrations of ACh, before 
(Panel a) and after incubation with L-NAME (Panel b and Panel c, n=9) or oxadiazolo-
quinoxaline (ODQ, Panel d, n=9). Data are mean ± S.E.M. Asterisks indicate significant 
differences (P<0.05). 
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Coronary arteriolar response to NO donors.  
Dilations to the NO donor, sodium nitroprusside (SNP) were also tested and 
interestingly found to be significantly increased in the arterioles isolated from obese rats, 
when compared to those of arterioles obtained from lean rats (Figure 5a). SNP- induced 
dilations were also obtained after administration of ODQ, an inhibitor of soluble guanylate 
cyclase. ODQ decreased SNP-induced dilations to the same level, thereby eliminating the 
NO-donor evoked differences in dilations between the two groups (Figure 5a). In separate 
series of experiments arteriolar responses were obtained to 8-bromo-cGMP, a cell permeable, 
stabile cGMP analog. We found that 8-bromo-cGMP elicited substantial dilations in coronary 
arterioles, which however were not significantly different in the two groups of vessels (Figure 
5b). 
 
 
Figure 5, Changes in diameter of coronary arterioles isolated from lean (n=18) and high fat 
diet-induced obese rats (n=19) in response to cumulative concentrations of sodium 
nitroprusside (SNP, Panel a) in the absence and presence of oxadiazolo-quinoxaline (ODQ, 
n=7, in each protocol). Changes in diameter of coronary arterioles isolated from lean and 
obese rats in response to cumulative concentrations of 8-bromo-cGMP (Panel b, n=7). Data 
are mean ± S.E.M. Asterisks indicate significant differences (P<0.05). 
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Immonocytochemistry.  
Basal and SNP-stimulated cGMP immunoreactivity were detected in native coronary 
arteriolar section in lean and obese rats. No specific labeling was detected in the section in 
which the first antibody was omitted. We have found that SNP-stimulated cGMP 
immunoreactivity was increased in coronary arterioles of lean and obese rats, and the 
enhancement found to be greater in coronary arterioles of obese rats (Figure 6a and 6b). 
 
 
Figure 6, Representative photomicrographs of immuncytochemistry (Panel a) and 
summarized data of densitometry analysis of 3 separate experiments (Panel b), showing 
cGMP immunoreactivity (indicated by the brown product) in the coronary arteriolar wall of 
lean and obese rats, with or without stimulation with SNP. Insets are representing 
experiments in which the first antibody was omitted (no 1
st
 ab). Scale bar, 50 μm, 
L=arteriolar lumen. Panel c: Basal and SNP-stimulated cGMP levels measured with ELISA 
in carotid arteries isolated from lean (n=5) and obese rats (n=5). Asterisks indicate 
significant differences (P<0.05). 
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cGMP ELISA.  
Basal and SNP-stimulated cGMP levels were directly measured in the carotid artery of 
lean and obese rats. We have found that basal cGMP levels were similar in vessels from lean 
and obese rats (Figure 6c). The NO donor, SNP elicited marked increases in cGMP levels in 
both groups, which tended to be increased in those of vessels from obese rats (Figure 6c). 
 
 
Western immonoblots.  
Western blot analysis was performed in single coronary arteries from both lean and 
obese rats. We have found that there were no significant differences in the eNOS protein 
expression (Figure 7a) and also in the soluble guanylate cyclase ß1 subunit protein levels in 
coronary arterioles of lean and obese rats (Figure 7b). 
 28 
 
 
 
Figure 7. Western blot analysis of eNOS (Panel a) and soluble guanylate cyclase (sGC) ß1 
subunit (Panel b) protein expression in single coronary arterioles of lean (n=5) and obese 
(n=5) rats. Anti–ß-actin was used to normalize for loading variations. Bar graphs are 
summary data of normalized densitometric ratios (1 vessel from each animal was used). 
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6. DISCUSSION 
 
Based on the findings discussed in the Background of this Dissertation we have raised 
the hypothesis that obesity activates as yet unknown mechanisms intrinsic to the vascular 
wall, aiming to maintain adequate tissue perfusion during the disease development. 
Accordingly, the first aim was to investigate the impact of obesity on to endothelium-
dependent and –independent dilations of the human brachial artery. 
In this set of experiments we have demonstrated that both flow-mediated dilations 
(FMD) and nitroglycerin (NTG)-induced dilations of brachial artery were significantly 
elevated in obese patients, when compared to lean hypertensive subjects. Correspondingly, a 
positive correlation between BMI and FMD and also BMI and NTG-induced brachial artery 
dilation in hypertensive patients was found. Correlations between BMI and FMD and also 
BMI and NTG-induced brachial dilations remained significant even after adjusting for age, 
which variable negatively correlated with FMD of the brachial artery. No significant 
associations were found when the magnitude of FMD and NTG-induced brachial artery 
relaxations were compared to other variables, such as gender, co-morbidities and medications. 
It should be noted that in this study there was a predominance of overweight and obese- 
hypertensive patients, when compared to those of lean-hypertensive individuals. This was 
taken into the account, when comparison of the results obtained from subgroups with different 
N numbers was accomplished by ANOVA. Moreover, the impact of BMI, being a continuous 
variable, was also evaluated by Pearson correlation, to validate the key impact of overweight 
and obesity on vasomotor responses. Although these analyses demonstrated a positive, rather 
than a negative (as one would expect) associations between BMI and FMD and also between 
BMI and NTG-induced brachial artery dilations, still, the possible influence of the 
predominance of overweight and obese subjects cannot be entirely excluded, which may limit 
the final conclusions drawn by this study. 
The mechanisms responsible for the observed effect of obesity on vascular function 
are likely to be complex. FMD of the brachial artery are considered being partly dependent on 
endothelium-derived relaxing factors, such as NO, whereas NTG-induced dilations are 
depend on the responsiveness of vascular smooth muscle to NO (42, 45). Because, both 
endothelium-dependent (NO agonist) and -independent (NO donor) induced brachial artery 
dilations were enhanced in obese patients, it is likely that primarily the enhanced sensitivity of 
vascular smooth muscle cells to NO is responsible for the observed alterations. Interestingly, 
recent studies, elucidating alterations in vasomotor function in animal models of obesity also 
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demonstrated preserved or even enhanced arterial dilations, although the exact mechanisms 
remained obscure (31, 60). A recent study has reported that in patients with morbid obesity, 
rapid weight reduction is associated with reduction of NO synthesis (44). These investigations 
support our present findings that in certain conditions, obesity could activate adaptive 
vascular mechanisms, among others by increasing the sensitivity of vascular smooth muscle 
to NO, aiming to maintain/enhance vasodilatory function of arterial vessels. 
To test this hypothesis the second aim was to investigate the impact of obesity on 
vasomotor function in animal model of obesity, which allow us a better evaluation of the 
possible cellular mechanisms involved in enhanced NO sensitivity.  
The vascular endothelium produces and secretes numerous compounds that regulate a 
variety of physiological functions, including vasomotor tone, coagulation, inflammation, 
permeability and cell adhesion (72). Among others, nitric oxide (NO) is considered to be one 
of the key molecules in maintaining normal vascular homeostasis and it is a major contributor 
to maintain adequate coronary microvascular tone (46). Solid evidence indicates that type 2 
diabetes is associated with impaired bioavailability of NO both in conduit vessels and 
resistance arteries (4, 24, 31, 47, 62, 66, 74). Studies have also demonstrated that obese 
subjects exhibit a reduced NO-mediated, agonist-induced dilation of cerebral, mesenteric, 
coronary and skeletal muscle microvessels (20, 24, 54). Interestingly, Brandes et al reported 
that a reduced endothelial NO production by acute administration of an NO synthase inhibitor 
in wild type mice or chronic deficiency of NO in eNOS knockout mice increase NO 
sensitivity of vascular smooth muscle cells in response to exogenous NO donors (7). They 
have proposed that an increased sensitivity of sGC to NO may compensate for the reduced 
NO synthesis (7). Because administration of exogenous NO decreased sGC activity acutely 
and over time its protein expression (63), it has been posited that NO may play an important, 
negative feedback regulatory role on the catalytic activity of the sGC, hence any reduction of 
NO level may lead to an enhancement of the sensitivity of sGC to NO. 
In this set of experiments we have found that in coronary arterioles (active diameter 
less than 100 μm) obtained from high fat diet-treated obese rats ACh-induced dilation was 
essentially preserved. Interestingly, we have found that in coronary arterioles of the obese rats 
pharmacological inhibition of NOS had no significant effect of ACh-induced dilations, while 
it reduced those responses in control vessels. This finding suggested either the lack of NO 
mediation or a reduction of the amount of the NO production in obese animals, which 
however cannot be detected by measuring diameter changes of arterioles in the presence of a 
NOS inhibitor. On the other hand, this finding also raised the possibility that in coronary 
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arterioles of obese rats, mechanisms intrinsic to vascular wall are activated to compensate for 
the reduced NO availability. In the coronary circulation oxygen extraction is near maximal 
(33), impairment of arteriolar dilator function could have significant consequence on tissue 
perfusion, leading to tissue ischemia. It is also known that any increase in body mass 
(muscular or adipose tissue) requires a higher cardiac output and expanded intravascular 
volume to meet the elevated metabolic requirements (22). Given that, in obesity coronary 
resistance vessels should adopt to increased coronary blood flow and metabolic requirements 
to maintain adequate tissue perfusion during the disease development. Our above-described 
human study provided evidence for the existence of such adaptation, by showing enhanced 
dilations to the NO-donor, compared to those of lean individuals. 
In the animal model, an attempt was also made to elucidate the possible underlying 
mechanism contributing to the observed functional adaptation of coronary microvessels in 
obese rats. Our findings show that in obese rats the sensitivity of coronary arterioles to NO 
was significantly enhanced, as demonstrated by augmented vasodilations to NO donor, 
sodium nitroprusside. Interestingly, enhanced dilations of coronary arteries to NO donor, SNP 
have been also described in female pigs fed with high fat diet, whereas NO-mediated coronary 
dilations to bradykinin were blunted (36). Collectively, these data suggest that an impaired 
NO availability in coronary microvessels of obese subjects can be associated with an 
enhanced NO sensitivity of the coronary arterioles and this mechanism may responsible for 
the maintained agonist-induced dilations, also found in the present study. 
Increased sensitivity for NO has been already proposed in previous observations in 
different conditions associated with impaired NO availability. For instance, both acute 
cessation of endothelial NO production in wild type mice or chronic deficiency of NO in 
endothelial NO synthase knockout mice increase NO sensitivity of vascular smooth muscle 
cells in response to nitrovasodilator agents (7). It has been posited that an enhanced sensitivity 
of the downstream sGC to NO may compensate for the reduced NO availability (7). In this 
context, it has been also found that acute administration of exogenous NO decreased sGC 
activity and in long-term its protein expression (30). These findings indicate that NO may 
play an important, negative feed back regulatory role on the catalytic activity of its effector, 
sGC, hence any reduction of NO level may lead to an enhancement of the sensitivity of sGC 
to NO. 
To demonstrate the possible involvement of enhanced sGC activation, our studies 
revealed that inhibition of sGC by ODQ reduced both ACh- and also NO donor (SNP)-
induced arteriolar dilations and, importantly, eliminated differences between responses of 
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coronary arterioles of lean and obese rats. We have also found that the stable cGMP analogue, 
8-bromo-cGMP elicited substantial dilations in coronary arterioles, which, however were not 
significantly different in the two groups of vessels. These findings indicate potential 
involvement of enhanced sGC activation in mediating enhanced sensitivity of smooth muscle 
cells for NO in coronary arterioles of obese rats. On the basis of the present findings only 
minor, if any, role can be ascribed for the contribution of other mechanisms, such as 
NO/peroxynitrite-dependent, S-glutathiolation-mediated activation of the sarco/endoplasmic 
reticulum calcium ATPase, which may also lead to an enhanced NO sensitivity, independent 
of sGC activation, as suggested previously (1). Furthermore, our cytochemistry data 
suggested a maintained or even enhanced SNP-stimulated cGMP immunoreactivity in the 
coronary arterioles of obese rats. To quantitate this observation in parallel experiments basal 
and stimulated cGMP contents were also measured in carotid arteries of lean and obese rats 
with cGMP ELISA. In this assay we have found no significant differences in the basal cGMP 
content, but detected elevated cGMP levels in SNP-stimulated vessels of lean and obese rats. 
Although, results obtained in a conduit vessel cannot be directly extrapolated to those of 
coronary microvessels, these data are in accordance with immunocytochemistry data obtained 
in coronary arterioles and suggest maintained or even increased sGC activation in obese 
animals. The results showing no changes in the protein expression of the sGC β1 subunit, 
along with the findings that 8-bromo-cGMP-evoked coronary dilations were similar in lean 
and obese rats suggest a primary role for enhanced activity of sGC enzyme in coronary 
arterioles of obese rats. 
An intriguing question namely what are the exact origin and nature of factor(s), which 
may contribute to the activation of sGC is still open. It seems plausible that lack of NO may 
lead to enhanced sGC sensitivity (7). It has been shown that TNFα-mediated vascular 
inflammation have important consequences with respect to downstream signaling of NO (25). 
In this study an attempt was made to estimate the level of systemic inflammation likely to be 
present in obese rats. To this end we have measured the serum levels of C-reactive protein 
(CRP), which however found to be comparable in lean and obese animals. This data suggest 
that in this model a manifest systemic inflammation is unlikely present, although a possible 
involvement of inflammation localized in the vascular wall cannot be entirely excluded and 
has yet to be elucidated in future studies. 
Collectively, we provided evidence for an enhanced NO sensitivity of coronary 
arterioles isolated from obese rats fed a high fat diet. We found that the enhanced sensitivity 
of coronary arterioles to NO was associated with increased activity of sGC in coronary 
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arterioles, in which a reduced NO bioavailability was also detected. Similar results were 
obtained in humans, showing that NO donor-induced brachial artery dilations were enhanced 
in patients with obesity.  
Although it seems plausible that the lack of NO release may lead to an enhanced 
activity of sGC in vascular smooth muscle cells (7), other studies demonstrated that an acute 
exposure to reactive oxygen species, i.e. H2O2 could also lead to activation of sGC, 
contributing to the relaxation of the bovine pulmonary artery (9, 75). Moreover, Bauersachs et 
al have shown that rats with heart failure exhibit increased expression of sGC, which was due 
to the enhanced vascular superoxide anion production (5). Since obesity is also associated 
with oxidative stress (19, 59), it is likely that ROS, in addition to their effect in reducing NO 
availability, may play a role in the activation of sGC, a hypothesis, which has yet to be tested. 
These data suggest that an impaired endothelial NO availability in coronary arterioles can be 
associated with an enhanced sensitivity to NO in vascular smooth muscle cells and that this 
mechanism may lead to compensation of the reduced NO-mediated vascular signaling in 
obesity. On the other hand, it has been demonstrated that oxidative and nitrosative stress can 
lead to inactivation of sGC over time (52); thus the question remains to be answered to what 
extent and how long up-regulation of sGC may compensate for the reduced NO-mediated 
vascular signaling, as obesity progress. 
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7. SUMMARY AND CLINICAL IMPLICATIONS 
 
Although obesity is widely accepted as a risk factor for coronary heart disease and 
heart failure, evidence also supports a role for obesity in cardiovascular protection. A growing 
number of recent reports document a statistically significant survival benefit in obese patients 
once they have been diagnosed with cardiovascular diseases (27, 28, 32). The conclusion that 
obesity may both elicit cardiovascular disease and protect from cardiovascular death now 
clearly requires further investigation at cellular, molecular, and systematic levels. 
At this time, we can only speculate regarding the physiological and/or clinical 
relevance of the present observation. The hallmark of essential hypertension is known to be an 
increased total peripheral resistance (43). With the progression of hypertensive cardiovascular 
disease, cardiac output begins to fall, and total peripheral resistance becomes more elevated. 
Conversely, any increase in body mass (muscular or adipose tissue) requires a higher cardiac 
output and expanded intravascular volume to meet the elevated metabolic requirements (43). 
An enhanced dilatory function of coronary arterioles may reflect increased coronary blood 
flow and metabolism caused by hyperdynamic circulation early in obesity. The increased NO 
sensitivity of coronary arterioles in obese individuals, revealed in the present study, might 
have beneficial effects regarding to the efficacy of nitrate therapy, as well as the prevalence of 
nitrate tolerance in this particular patient population, which has yet to be elucidated. 
Taken together, our studies demonstrated a close association between obesity and the 
magnitude of dilations of coronary microvessels and peripheral conduit arteries. Obesity 
seems to activate intrinsic vascular mechanisms, such as increased NO sensitivity, implying 
an important functional adaptation of arterial vessels in the coronary and peripheral 
circulation to the presence of obesity. Understanding the sequence of pathological events in 
obesity-related microvascular dysfunction and adaptation might provide a rationale for 
therapeutic interventions and it might well harness these effects for therapeutic purposes. 
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8. ÖSSZEFOGLALÁS 
 
A metabolikus szindróma egy kardiovascularis rizikófaktorokat, metabolikus változásokat 
magába foglaló komplex eltérés, amely jelentősen megnöveli a szívelégtelenség, és az 
ischaemias szívbetegség kialakulásának kockázatát. Az obezitás és a hozzá kapcsolódó 
metabolikus diszfunkció a metabolikus szindróma előfordulásában vezető tünet. A 
kardiovascularis halálozás előfordulása a jelenlévő rizikófaktorok számával arányosan 
növekszik Úgy tűnik, hogy a túlsúly a kardiovascularis funkcióra hátrányos hatással van, de a 
koronária mikroerek vazomotor regulációjára gyakorolt átfogó hatása még nem pontosan 
tisztázott. Metabolikus szindrómában a koronaria mikroerek vazomotor funkciójának 
károsodása alakulhat ki, amely a miokardialis diszfunkció kialakulását eredményezheti. 
A disszertációban az obezitás hatását vizsgáltuk a vazomotor funkcióra a nagy 
arteriákban, és a koronária arteriolákban. Azt találtuk, hogy az túlsúlyos betegek arteria 
brachialisában a flow-mediálta, és a nitroglicerin-indukálta dilatáció, és a body-mass index 
(BMI) között pozitív korreláció mutatható ki. Diéta indukálta obes állatmodell segítségével 
bebizonyítottuk, hogy a solubilis guanilát cikláz (sGC) aktivitásának fokozódása 
következtében a vascularis simaizom sejtek érzékenysége nitrogén-oxidra megnövekszik, ami 
a koronária arteriolák vasodilatációjának növekedését eredményezheti. A túlsúlyos egyedek 
arteriái adaptálódnak a hemodinamikai változásokhoz up-regulációs sejtmechanizmusokon 
keresztül. A mechanizmus jobb megértése hozzájárulhat a vascularis adaptációhoz, 
bepillantást adhat a patológiai események sorozatába obesitas esetén, és ezen hatások terápiás 
célra történő felhasználását segítheti. Jelenleg még nagy kihívást jelent a morbiditás és 
mortalitás csökkentése a metabolikus szindrómában szenvedő betegek körében.  
A munkám során célul tűztük ki, megvizsgálni az obezitás hatását a humán arteria 
brachialis endothelium dependens, és –independens vazodilatációjára.  
Valamint megvizsgálni az obezitás hatását állatmodellben a koronária arteriolák vazomotor 
funkciójára, megvizsgálni a vascularis adaptációt, és feltérképezni a folyamatban részt vevő 
sejtszintű mechanizmusokat. 
A metabolikus szindrómában a nagyerek atherosclerosisának idő előtti kialakulása 
figyelhető meg. Az atherosclerosis korai fázisában az endothel diszfunkció már kimutatható, 
mielőtt az érfal strukturális elváltozásai kialakulnának. A koronaria mikroerek működésének 
károsodása a szív szöveti keringésének megváltozásához vezet, ami aztán ischaemias 
szívkárosodás formájában nyilvánulhat meg.  
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Humán vizsgálatok során a nagy arteriák (arteria brachialis) endothel funkcióját a 
végtag 5 percig tartó leszorítása utáni felengedés hatására kialakuló érátmérő változásával 
vizsgáltuk, mely az áramlásfüggő endothel-dependens dilatációval áll kapcsolatban. 
Vizsgálatunkban az arteria brachialisban mérhető flow-mediálta vazodilatáció (FMD) és a 
nitroglicerin-mediálta vazodilatáció szignifikánsan magasabb volt az obes betegek 
csoportjában (BMI>30), mint a sovány betegek esetében (BMI<25) A BMI és az FMD, és a 
BMI és a nitroglicerin –indukálta dilatáció között is pozitív korrelációt találtunk. 
Állatkísérletek során az elhízás szintén az endothelfüggő érválasz károsodásához 
vezetett. Az endothel függő dilatációt acetilkolin (ACh) segítségével vizsgáltuk kövér és 
sovány patkányok koronaria arterioláin. Az ACh kiváltotta érválaszokat az endotheliális NO 
szintázt gátló N-nitro-L-arginin-metilészter (L-NAME) 30 perces inkubációját követően is 
megvizsgáltuk. Ezt követően az arteriolák ACh-ra adott érválaszát szolubilis guanilát cikláz 
(sGC) gátló oxadiazolo-quinoxaline (ODQ) 30 perces inkubációját követően is megmértük 
mindkét csoportban. NO donorként a sodium nitroprusszid-ot (SNP) használtuk, és az 
endothel-independens dilatáció tekintetében vizsgáltuk az SNP dózisfüggő hatásait. A NO 
donor, SNP hatására kialakuló érválaszokat a szolubilis guanilát cikláz (sGC)-gátló 
oxadiazolo-quinoxaline (ODQ) 30 perces inkubációját követően is megmértük. Az sGC 
aktivitást meghatároztuk mind a sovány, mind az elhízott állatok koronaria arterioláiban a 
cGMP szint meghatározásával immunkémiai módszerekkel kiindulási állapotban, és nitrogén 
donor, SNP jelenlétében, valamint megmértük carotis arterián is ELISA módszert alkalmazva 
Vizsgáltuk a sejtpermeabilis, cGMP-analóg 8-bromo-cGMP emelkedő koncentrációinak 
hatására bekövetkező érválaszt is. Western immunoblott technikával. 
Eredményeinket tekintve ACh hatására fellépő, endothel-dependens dilatáció 
szempontjából a sovány és kövér patkányokból nyert erek válaszában nem volt szignifikáns 
különbség. A NO szintézis L-NAME-al történő gátlása csak a sovány állatokból nyert 
koronária arteriolákban csökkentette az ACh-kiváltotta dilatációt, a kövér patkányok 
koronária arterioláiban bekövetkezett dilatációra azonban ez nem volt hatással. Ebből arra 
lehet következtetni, hogy a kövér patkányokban a koronária arteriolák NO szintézise 
károsodik.Az ACh válasz azonban azt sugallta, hogy a károsodott NO szintézis ellenére a 
kövér patkányok arterioláinak ACh által kiváltott dilatációja megtartott marad, aminek a 
hátterében eddig nem ismert kompenzatorikus mechanizmusok aktiválódása állhat. A NO 
donor, a natrium nitroprusszid (SNP) hatására kialakuló endothelium-independens dilatáció a 
kövér patkányokban szignifikánsan nagyobb volt, a kontroll csoport arterioláinak érválaszával 
összehasonlítva. Ez arra enged következtetni, hogy a túlsúlyos patkányok koronária 
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mikroereiben az arterioláris simaizom NO érzékenysége fokozódik. A cGMP analóg 8-
bromo-cGMP által kiváltott dilatáció nagysága nem különbözött a két csoport állataiból 
izolált erek válaszaiban, a 8-bromo-cGMP ugyanolyan mértékű dilatációt eredményezett 
mindkét csoportban. A fokozott NO érzékenység hátterében tehát a cGMP fokozott 
termelődése állhat. Ezt erősítette meg az az eredmény, miszerint a solubilis guaniláz cikláz 
(sGC) gátló, oxadiazolo-quinoxalin (ODQ) jelenlétében a SNP kiváltotta vazodilatáció, a 
sovány és túlsúlyos patkányok ereiben nem különbözött egymástól, vagyis a sGC gátlása a 
NO donor kiváltotta dialtációt ugyanolyan szintre csökkentette. Tehát eltűnt a két csoport 
között gátlószer nélkül meglévő különbség. Immunkémiai módszerekkel a kövér állatok natív 
koronária arterioláiban a SNP stimulálta cGMP szint szignifikánsan magasabb volt a sovány 
állatokhoz képest. A cGMP szintet meghatároztuk carotis arteriákban ELISA módszerrel is, 
melynek során az előzőhöz hasonló eredményre jutottunk. Alapállapotban a cGMP szint 
csaknem azonos volt a két csoportban, majd a NO-donor SNP-t hozzáadva a cGMP szint 
mindkét csoportban emelkedett, de a kövéreknél nagyobb mértékben. Feltételezhető, hogy a 
fokozott cGMP termelés hátterében a szolubilis guanilát cikláz (sGC) megnövekedett 
expressziója állhat, ezért megvizsgáltuk az eNOS protein expresszióját, és a sGC β1 
alegységének protein szintjét Western immunoblott technikával. A vizsgálat során azonban 
nem találtunk különbséget egyik esetben sem a két vizsgált csoport vonatkozásában. Tehát ez 
azt a következtetést támasztja alá, hogy a fokozott cGMP termelődést, és ennek 
következtében a fokozott dilatációt a solubilis guanilát cikláz aktivitásának, és nem a 
termelődésének a fokozódása eredményezi.  
Az endoteliális NO szintézis hiányában a sGC aktivitása kompenzatórikusan 
fokozódik. A megnövekedett sGC aktivitás hátterében álló mechanizmusok jelenleg még nem 
teljesen tisztázottak. A kísérletek alapján arra lehet következtetni, hogy az elhízás eddig 
ismeretlen adaptációs vascularis mechanizmusokat aktivál a koronaria mikroerek falában, 
aminek hatására a károsodott dilatáció kompenzálódása következik be. Ezáltal képes 
biztosítani a megfelelő myocardialis szöveti perfúziót. Elképzelhető, hogy metabolikus 
szindrómában a megnövekedett oxidatív stressz nem csupán az endothelium működését 
befolyásolja, de hatással lehet az érfal simaizom mediálta vazoregulációs mechanizmusaira is. 
Ezáltal fokozhatja a sGC aktivitását, ami a koronária arteriolák adaptációs folyamatait 
aktiválja. Mindezek alapján megállapítható, hogy az elhízás során a koronária mikroerek NO 
szintézise károsodik, azonban a sGC aktivitásának fokozódásával az arterioláris simaizom NO 
érzékenysége is fokozódik. A metabolikus szindrómában ezek a folyamatok jelentős szerepet 
játszhatnak a koronária mikrokeringés fenntartásában.  
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